Canadian pharmaceutical company Apotex Inc. is considering an initial public offering on the Toronto Stock Exchange in the first half of the year. According to Bloomberg, citing sources, the deal could be worth up to C$1 billion (approximately $730 million).

If plans are implemented, the offering would be the largest IPO in Canada since 2021. RBC Capital Markets, Jefferies Financial Group, and TD Securities are serving as financial advisors. The agency's sources note that the final terms of the deal, including the timing and size of the offering, have not yet been finalized and are subject to adjustment.

In 2023, Apotex was acquired by investment firm SK Capital Partners. Sources estimated the deal value at C$3 billion to C$4 billion.